...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of oncology >Overexpression of Kynurenine 3-Monooxygenase Correlates with Cancer Malignancy and Predicts Poor Prognosis in Canine Mammary Gland Tumors
【24h】

Overexpression of Kynurenine 3-Monooxygenase Correlates with Cancer Malignancy and Predicts Poor Prognosis in Canine Mammary Gland Tumors

机译：kynurenine 3-单氧基酶的过度表达与癌症恶性肿瘤相关，并预测犬乳腺肿瘤的预后差

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tumor biomarkers are developed to indicate tumor status, clinical outcome, or prognosis. Since currently there are no effective biomarkers for canine mammary tumor (CMT), this study intended to verify whether kynurenine 3-monooxygenase (KMO), one of the key enzymes involved in tryptophan catabolism, is competent for predicting prognosis in patients with CMT. By investigating a series of 86 CMT clinical cases, we found that both gene and protein expression of KMO discriminated malignant from benign CMTs and was significantly higher in stage IV and V tumors than in lower-stage CMTs. About 73.7% of malignant CMTs showed strong expression of KMO which correlated with lower overall survival rates in patients. Further, downregulation of KMO activity significantly inhibited cell proliferation of CMT cells. Taken together, the findings indicated that KMO is a potential biomarker for tumor diagnosis, and this might open up new perspectives for clinical applications of CMT.
机译：开发肿瘤生物标志物以表明肿瘤地位，临床结果或预后。此后，目前没有有效的犬乳腺肿瘤生物标志物（CMT），本研究旨在验证kynurenine 3-单氧基酶（KMO），其中一项参与色氨酸分解代谢的关键酶之一，是否能够赋予CMT患者的预后。通过调查一系列86厘吨临床病例，我们发现KMO的基因和蛋白质表达来自良性CMTS的恶性恶性肿瘤，阶段IV阶段和V肿瘤明显高于阶段的CMTS。大约73.7％的恶性CMTS显示出强烈的KMO表达，与患者的较低总体存活率相关联。此外，对kmo活性的下调显着抑制CMT细胞的细胞增殖。在一起，调查结果表明，KMO是肿瘤诊断的潜在生物标志物，这可能对CMT的临床应用开辟了新的视角。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号